Aprepitant is a novel, selective activator of the K2P channel TRAAK by McCoull, D. et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
McCoull, D., Veale, E.L., Walsh, Y., Byrom, L., Avkiran, T., Large, J.M., Vaitone, E., Gaffey,
F., Jerman, J., Mathie, A. and  and others  (2021) Aprepitant is a novel, selective activator of
the K2P channel TRAAK.   Biochemical and Biophysical Research Communications, 588 .  
pp. 41-46.  ISSN 0006-291X.
DOI
https://doi.org/10.1016/j.bbrc.2021.12.031





Biochemical and Biophysical Research Communications 588 (2022) 41e46Contents lists avaiBiochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate/ybbrcAprepitant is a novel, selective activator of the K2P channel TRAAK
D. McCoull a, *, E.L. Veale b, Y. Walsh b, L. Byrom a, T. Avkiran a, J.M. Large a, E. Vaitone a,
F. Gaffey a, J. Jerman a, A. Mathie b, c, P.D. Wright a
a LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
b Medway School of Pharmacy, University of Greenwich and University of Kent, Anson Building, Central Avenue, Chatham Maritime, Kent, ME4 4TB, UK
c School of Engineering, Arts, Science and Technology, University of Suffolk, Ipswich, IP4 1QJ, UKa r t i c l e i n f o
Article history:
Received 9 December 2021
Accepted 12 December 2021








E-mail address: david.mccoull@lifearc.org (D. McC
https://doi.org/10.1016/j.bbrc.2021.12.031
0006-291X/© 2021 The Authors. Published by Elseviea b s t r a c t
TRAAK (KCNK4, K2P4.1) is a mechanosensitive two-pore domain potassium (K2P) channel. Due to its
expression within sensory neurons and genetic link to neuropathic pain it represents a promising po-
tential target for novel analgesics. In common with many other channels in the wider K2P sub-family,
there remains a paucity of small molecule pharmacological tools. Specifically, there is a lack of mole-
cules selective for TRAAK over the other members of the TREK subfamily of K2P channels. We developed
a thallium flux assay to allow high throughput screening of compounds and facilitate the identification of
novel TRAAK activators. Using a library of ~1200 drug like molecules we identified Aprepitant as a small
molecule activator of TRAAK. Aprepitant is an NK-1 antagonist used to treat nausea and vomiting. Close
structural analogues of Aprepitant and a range of NK-1 antagonists were also selected or designed for
purchase or brief chemical synthesis and screened for their ability to activate TRAAK. Electrophysiology
experiments confirmed that Aprepitant activates both the ‘long’ and ‘short’ transcript variants of TRAAK.
We also demonstrated that Aprepitant is selective and does not activate other members of the K2P
superfamily. This work describes the development of a high throughput assay to identify potential
TRAAK activators and subsequent identification and confirmation of the novel TRAAK activator Apre-
pitant. This discovery identifies a useful tool compound which can be used to further probe the function
of TRAAK K2P channels.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There continues to be significant interest in examining and
modulating the function of the 15 members of the two-pore
domain potassium channel family (K2Ps) [1]. This has stemmed
from a growing body of genetic and functional studies linking their
known effects on establishing and maintaining resting membrane
potential to pathophysiological conditions [2]. Concomitantly, a
greater recent understanding of the structural characteristics [3]
and expression profiles [4] of these channels is also driving interest
in their potential as therapeutic targets, in particular with respect
to pain-related phenotypes.
Among the three members of the TREK sub-family, the TRAAK
channel (encoded by the KCNK4 gene, also referred to as K2P4.1) [5]
is the most distinct in terms of structural homology [6], whilstoull).
r Inc. This is an open access articlretaining some similarities in responses to certain lipids and to
mechanical and thermal stimuli. It has been shown that TRAAK is
expressed in dorsal root ganglia (DRG) and trigeminal ganglia (TG)
neurons by measuring K2P mRNA abundance using RT-qPCR [7]. In
normal rodent DRG neurons [7] it was reported that TRAAK mRNA
was the second highest in abundance of the K2P family. This is in
agreement with earlier in-situ hybridisation studies which showed
TRAAK expression to be enriched in the DRG (human and rodent),
and that TRAAK is predominantly expressed in the CNS (with little
peripheral expression) [8]. TRAAK channels are highly expressed at
the Nodes of Ranvier [9,10] where they are required for rapid action
potential repolarisation [11].
In mouse models, it has been shown that TRAAK KO mice have
increased responses to mechanical and thermal stimuli [12]. In this
study, it was also shown that TRAAK and TREK-1 channels reduce
excitability of heat nociceptors, by acting as a counterbalance to
depolarisation [12]. Similarly, there is growing evidence linking the
TRAAK channel to the pain therapeutic space. At the wider genomic
level, it was observed that polymorphisms were associated withe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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validated than TREK-1 or TREK-2, the TRAAK channel is increasingly
thought to represent an attractive target for the treatment of pe-
ripheral neuropathic pain.
Activation of TRAAK by small molecules has been described,
chiefly by non-selective activators of the closely related TREK-1 and
TREK-2 channels. Compounds such as C3001a [14], BL-1249 [15],
Flufenamic acid [16], ML67-33 [17], DCPIB [18], 2-APB [19], Arach-
idonic acid [5] and a group of phospholipid modulators [20] have
been reported to activate the TRAAK channel at a number of distinct
binding sites. Hence, despite TRAAK's potential role in neuronal
excitability and therefore its potential utility as a target for novel
analgesics [21], there remains a requirement for selective small
molecule activators of TRAAK with which to probe its function in
more detail.
Our experience in target-class screening to identify small
molecule activators of K2P channels, using a thallium flux assay
[22] has resulted in the discovery and characterisation of selective
activators of several channels in this family [23e25]. Here we
describe a recent application of this work, which has identified an
activator of the TRAAK channel with selectivity against the TREK-1
and TREK-2 sub-family members. Further, we have confirmed and
characterised this activity in more detail, in the context of other
K2P channel selectivity and whole cell patch clamp electrophysi-
ology experiments.
2. Materials and methods
2.1. Thallium flux assays
Cells transiently expressing TRAAK (NM_033310.2) were
generated using U-2 OS cells and TRAAK Baculovirus (BacMam) (5%
v/v). For methods detailing transfection and thallium flux assay
protocols see Ref. [22]. The TRAAK variant used for thallium flux
studies corresponds to the ‘short’ variant described in whole-cell
patch voltage clamp experiments. Channel activity in thallium
flux experiments was defined as the rate of fluorescence increase,
over the pre-addition baseline, between 15 and 25 s following
thallium addition. For selectivity assays also see Ref. [22].
2.2. Whole-cell patch clamp electrophysiology
The methods used in this study for tissue culture and trans-
fection of tsA201 cells have been described previously [26]. Briefly,
for electrophysiological experiments, pcDNA3.1 was cloned with
the gene of interest. These vectors, along with a green fluorescent
protein (GFP) expressing vector, were transiently transfected into
tsA201 cells using the calcium phosphate method. The cells were
used for experiments the next day. Currents were recorded from
tsA201 cells using whole-cell patch-clamp in the voltage clamp
configuration. Cells were placed in the recording chamber filled
with an external solution which contained (in mM): 145 NaCl, 2.5
KCl, 3 MgCl2, 1 CaCl2, and 10 HEPES (pH 7.4 using NaOH). Patch
clamp glass pipettes were pulled from thin-walled borosilicate
glass with resistances between 3 and 6 MU. The glass pipette in-
ternal solution consisted of (in mM): 150 KCl, 3 MgCl2, 5 EGTA, and
10 HEPES (pH 7.4 using KOH) [24].
K2P currents were studied using a step-ramp voltage protocol
[25] from a holding potential of 60 mV. Each sweep of the pro-
tocol lasted for 1.5 s, including sampling at the holding potential
and sweeps were repeated once every 5 s. For analysis of outward
current, we measured the difference current from steps
between 40 mV and 80 mV. Currents were recorded using an
Axoclamp 1D (Molecular Devices, Sunnyvale, CA, USA) amplifier
and stored and analysed using pClamp 10.2 software (Molecular42Devices).
2.3. Compounds
Aprepitant was purchased from Tocris BioScience (United
Kingdom). Fosaprepitant was purchased from BioTechne (United
Kingdom). ent-Aprepitant, desfluoro Aprepitant, Aprepitant-M2
and Aprepitant-M3 were purchased from Carbosynth Ltd (United
Kingdom). GR 203040, CP 99994, CP 122721, L-733,060, L-732,138
and L-760,735 were all purchased from BioTechne (United
Kingdom). LA-TRAAK-1 to LA-TRAAK-6 were synthesised by
adapting previously published synthetic procedures, as referenced
in the main text. The TASK-3 inhibitor (compound 3 in Ref. [27]),
was purchased from AKos (Germany).
3. Results
3.1. Identification of novel TRAAK activators
To address the lack of pharmacological tools to investigate this
channel, we sought to develop a cell-based assay that would enable
us to identify small molecule activators of TRAAK. Using the
approach previously described in Ref. [22] a fluorescence-based
thallium flux screen was developed. The key requirement in the
development of these assays is to identify conditions which facili-
tate the identification of activators, that is, to confirm an appro-
priate level of channel (TRAAK) expression. To do this, cells were
initially transduced with differing levels of human TRAAK BacMam.
Fig. 1A shows that as the level of BacMam added (% v/v) increased,
so did the rate of fluorescence increase within cells upon the
addition of thallium. This was taken as confirming we observed an
increase in cellular levels of TRAAK channel expression. A BacMam
concentration of 5% was chosen as this was not the maximum, and
thus facilitated the identification of activators. In other words, the
expression level was appropriate to allow sufficient dynamic range
to measure an increase in signal [22]. It should also be noted that,
for all concentrations of BacMam tested, the magnitude of the
TRAAK signal observed in the thallium flux assay was low
compared to othermembers of the TREK family [25]; this is perhaps
reflective of the native TRAAK biology and the channel's open
probability [28].
Using knowledge gained from previous screens, wewere able to
use our ‘target-class’ [22] approach to rapidly adapt conditions to
generate a high throughput assay. This involved building on pre-
vious observations of K2P screens and using existing in-house
automation methods and liquid handling techniques. A library of
~1200 drug-like molecules was screened which led to the identi-
fication of a robust and novel activatore Aprepitant (Fig. 1B and see
Supplementary Material for structure). This compound is used
clinically to prevent chemotherapy-induced nausea and vomiting
(CINV) [29,30]. A second activator from this library was also iden-
tified, Fosaprepitante a pro-drug of Aprepitant and a highly similar
structure. Both these molecules act as antagonists at the G-Protein
coupled receptor NK-1, a member of the Tachykinin receptor family.
Neither compound showed an increase in fluorescence in non-
transduced U-2 OS cells (data not shown).
We then compared the activity of Aprepitant to other tool
compounds which have previously been demonstrated to show
activity at TRAAK or are known activators of the closely related
TREK-1 or TREK-2 channels - BL-1249, Prostaglandin F2a, GI-
530159, Phorbol-2-myristate, TPA, ML-402 and ML-67-33
(Fig. 1C). Of these only G-531059, at high concentrations, showed
a robust activation of TRAAK. EC50 determinations were also diffi-
cult due to the lack of definedmaximal asymptote. Interestingly, GI-
530159 has previously been shown to not possess TRAAK activator
Fig. 1. Using thallium flux to identify activators of TRAAK. (A) Titration of TRAAK BacMam. As BacMam levels increase (% v/v) there is an increase in the rate of cellular fluorescence
after the addition of thallium. This is representative of increased TRAAK channel activity. (B) TRAAK activity is increased after addition of Aprepitant or Fosaprepitant. Bar graphs
display average rate of fluorescence increase after the addition of thallium in the presence of DMSO, Aprepitant and Fosaprepitant (n  3, ±standard deviation). (C) Pharmacology of
TREK family activators using thallium flux to measure activation of TRAAK. Data shows compound response curves of BL-1249, 11-deoxy prostaglandin F2a (PGF- 2a), GI-530159,
phorbol-2-myristate (PMA), tetrapentylammonium (TPA), ML-402 and ML-67-33. All data show rate of fluorescence increase between 15 and 25 s n  3, ±standard deviation.
Table 1
Activity of Aprepitant analogues and NK-1 antagonists. Activity defined as
maximum % activity observed relative to 30 mM GI-530159. For all data activity is
shown at 10 mM, except for Fosaprepitant, L-732,138 and L-760,735 for which
activity is shown at 30 mM. L-760,735 also showed an effect on non-transduced
cells. Compounds which showed less than 20% activity of 30 mM GI-530159
were defined as inactive. Data is n  3, ±standard deviation. For structures of
compounds please see Supplementary Material.
Compound name and number Activity at TRAAK
Aprepitant (S1) 52.4 ± 5.9
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cellular background between the studies or to our use of thallium
flux and not electrophysiology to study GI-530159's activity. In
addition, given that we only saw robust activation at concentra-
tions greater than or equal to 10 mM and the authors of [31] used a
maximum of 10 mM, this observation may be explained by subtle
shifts in potency due to assay conditions, the isoform of TRAAK
channel studied, liquid handling techniques or a combination of
these differences.Fosaprepitant (S2) 53.0 ± 6.6
ent-Aprepitant (S3) 56.3 ± 7.9
desfluoro Aprepitant (S4) 54.2 ± 5.1
Aprepitant M2 (S5) INACTIVE
Aprepitant M3 (S6) 22.9 ± 1.2
GR 203040 (S7) INACTIVE
CP 99994 (S8) INACTIVE
CP 122721 (S9) INACTIVE
L-733,060 (S10) INACTIVE
L-732,138 (S11) 21.7 ± 1.5






LA-TRAAK-6 (S18) INACTIVE3.2. Exploring compound SAR
As described, Aprepitant (S1, see supplementary material for
chemical structures of all compounds S1 e S18) is an orally active
NK-1 receptor antagonist, given to alleviate post-operative and
chemotherapy induced emesis [29,30]. The more soluble pro-drug
Fosaprepitant (S2) is an effective intravenous alternative. We first
purchased and screened commercially available close analogues
and metabolites of Aprepitant (S3 e S6, supplementary material)
among which we found additional active compounds in the form of
ent-Aprepitant (S3), desfluoro Aprepitant (S4) and the metabolite
Aprepitant M3 (S6), although (S6) showed a lower but reproducible
activation (Table 1). These data again highlighted ‘tight’ SAR space
which has been previously associated with activators of K2P
channels of different chemotypes and binding sites. We also pur-
chased a small number of additional NK-1 antagonists (S7e S12), to
probe for any link to activity around the well-described NK-1
pharmacophore. Many are structurally related to Aprepitant, by
virtue of their saturated 6-membered ring core structures which
allow other chemical substituents to occupy similar positions in 3D43space as those on the Aprepitant molecule. Where the core struc-
ture is non-cyclic (as in S11), the positions of the substituents still
hold broadly to this pharmacophore. When S7e S12 were screened
using the thallium flux assay, only two compounds (S11 and S12)
showed activity at TRAAK, again at lower but reproducible levels.
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structures to Aprepitant itself, so would perhaps be more likely to
maintain some activity. A small number of close analogues of
Aprepitant (S13 e S18) were also selected and synthesised by
modifying previous procedures [32]; this was with a view to
assessing possible divergence from known NK-1 structure activity
relationships. These analogues were chosen to probe the impact of
differing stereochemistry at the key chiral centres or the alteration
of the morpholine N-substituent, to attempt to locate further active
analogues of this chemotype. In some cases, these more subtle
structural changes were hoped to maintain activity within a nar-
rower chemical SAR space. However, none of S13 e S18 were found
to show any activity upon screening against TRAAK. Taken together,
these initial data suggest that the binding site for TRAAK activation
is not shared with the site for NK-1 antagonism, although likely
further exemplar compounds would need to be identified and
screened to prove this empirically.3.3. Selectivity of Aprepitant
To confirm the utility of Aprepitant as tool activator of TRAAK
we next sought to investigate its selectivity against other members
of the K2P superfamily. Due to differing intrinsic properties of each
channel being tested and different sensitivity to activation for each
assay, the comparison of activation across channels is complex, and
it is important to include pharmacological tools for each channel
being analysed. This is challenging when appropriate and selectiveFig. 2. Selectivity of Aprepitant at K2P channels. Aprepitant was screened at multiple K2P
screened. Exemplar curves show rate of fluorescence increase (n  2, ±standard deviation)
44tools do not exist for many K2P channels. Aprepitant did not show
significant activation of any channel screened. Importantly this
includes the closely related TREK-1 and TREK-2 channels. As Fig. 2
shows, activity was only just above baseline and marginal
compared to known TREK activators. Interestingly, Aprepitant
showed some inhibition at a subset of other channels. At TRESK,
partial inhibition (compared to TPA) was observed. At TASK-2,
Aprepitant inhibited the channel but was less potent than TPA.
Given the lack of selectivity of TPA and the potential for non-
specific reductions in signal in the thallium flux assay, these ob-
servations will need to be further investigated and confirmed using
electrophysiology. Taken together, however, this data is highly
suggestive that Aprepitant does not activate other K2P channels.3.4. Whole-cell voltage-clamp recordings of the effect of Aprepitant
on human TRAAK channel currents
Two isoforms of human (h) TRAAK were studied using whole-
cell patch-clamp electrophysiology. These were a “short” form
(the normal isoform used in studies of recombinant channels and
that used for the thallium flux assays above - 393 aa, GenBank:
AF259500) and a “long” form (419 aa, GenBank: AF259501), where
the differences in length are due to differences in the N terminus
that precedes the first transmembrane domain of the channel [33].
The effect of Aprepitant (10 mM) was investigated on short TRAAK
and long TRAAK channel currents in whole-cell patch-clamp re-
cordings both by incubating cells in the compound and by acutechannels using thallium flux. Where available tool activators and inhibitors were also
.
Fig. 3. Enhancement of TRAAK channel currents by Aprepitant (10 mM). Current density (measured as the difference current between 40 and 80 mV, see methods) for cells
transfected with the short form (A) and the long form (B) of TRAAK in the presence and absence of Aprepitant (10 mM). The middle panels show representative current-voltage
relationships for currents through the short (C) and long (D) forms of TRAAK in the absence (black trace) and presence (blue trace) of Aprepitant (10 mM). Acute application of
Aprepitant (10 mM) to individual cells also enhances current through both the short (E) and long (F) forms of TRAAK. (For interpretation of the references to colour in this figure
legend, the reader is referred to the Web version of this article.)
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Fig. 3A and C shows that incubation with Aprepitant (10 mM)
significantly (P < 0.0001, two-tailed, unpaired t-test) enhances
current through the short form of the TRAAK channel by 7.7- fold,
from 4.8 pA pF1 (n ¼ 8, 95% CI: 3.0e6.7) in the absence of the
compound to 37.0 pA pF1 (n ¼ 5, 95% CI: 34.0e40.0) in its pres-
ence. Fig. 3B and D shows that incubation with Aprepitant (10 mM)
also significantly (P < 0.01) enhances current through the long form
of the TRAAK channel by 5.3-fold (slightly less than that seen for
the short form), from 3.6 pA pF1 (n ¼ 4, 95% CI: 2.6e4.7) in the
absence of the compound to 19.0 pA pF1 (n¼ 5, 95% CI: 12.5e25.7)
in its presence.
Perfusion of the compound to individual cells (Fig. 3E and F)
confirmed the observations above that Aprepitant enhances cur-
rent through both forms of the channel. However, as with incuba-
tion, Aprepitant was slightly more effective at enhancing current
through the short form of the channel. Aprepitant (10 mM)
enhanced current through the short form of the TRAAK channel by
599% of the control current (n ¼ 3, 95% CI: 409e789), whilst
Aprepitant (30 mM) enhanced current through the long form of the
TRAAK channel by 183% of the control current (n ¼ 5, 95% CI:
121e245). In contrast to the results with TRAAK channels, Apre-
pitant (10 mM) had no significant (p < 0.05) effect using a two tailed,
unpaired t-test on non-transfected cells and did not enhance cur-
rent through either hTREK-1 or hTREK-2 channels. For hTREK-1,
current was 40.3 pA pF1 (n ¼ 5, 95% CI: 16.3e64.3) in the
absence of the compound and 30.9 pA pF1 (n ¼ 5, 95% CI:
24.0e37.8) in its presence. For hTREK-2, current was 40.0 pA pF1
(n ¼ 7, 95% CI: 28.7e51.2) in the absence of the compound and
32.1 pA pF1 (n ¼ 10, 95% CI: 23.8e40.3) in its presence.
In conclusion, Aprepitant is a novel activator of TRAAK, which
shows selectivity for TRAAK over other K2P channels, identified
through a novel thallium flux screen and subsequently confirmed
through whole-cell manual patch-clamp electrophysiology. As45such, Aprepitant is a useful tool compound for identifying TRAAK
channels in native systems andmay form the basis for the synthesis
of future selective activators of TRAAK channels as potential ther-
apeutic agents in the treatment of pain.
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